Mi­tra Biotech, Glen­mark to ad­vance im­munoon­col­ogy port­fo­lio

BioSpectrum (India) - - COMPANY NEWS -

Mi­tra Biotech has an­nounced a part­ner­ship with Glen­mark Phar­ma­ceu­ti­cals fo­cused on ad­vanc­ing Glen­mark’s pro­pri­etary im­muno-on­col­ogy drug pipe­line uti­liz­ing Mi­tra’s CANscript plat­form. CANscript is a hu­man, im­mune-rel­e­vant ex vivo plat­form that al­lows drug de­vel­op­ers to un­der­stand drug per­for­mance in hu­man tis­sue, which in turn al­lows for an in­formed ap­proach to clin­i­cal de­vel­op­ment and pa­tient re­sponse. CANscript recre­ates the in vivo tu­mor mi­croen­vi­ron­ment, main­tain­ing the het­ero­gene­ity of the tu­mor while pre­serv­ing its im­mune com­part­ment.

This uniquely po­si­tions the plat­form to pro­vide drug de­vel­op­ers with an­swers to mech­a­nis­tic ques­tions about their im­munoon­col­ogy drug can­di­dates and pri­or­i­tize the most promis­ing can­di­dates for ad­vance­ment into clin­i­cal tri­als. Glen­mark’s im­muno-on­col­ogy pipe­line cur­rently in­cludes three bis­pe­cific mon­o­clonal an­ti­body (bsAb) can­di­dates be­ing stud­ied in a wide range of tu­mor types. GBR 1302, a HER2xCD3 bsAb and GBR 1342, a CD38XCD3 bsAb are cur­rently in Phase 1; and GBR 1372, an EGFRxCD3 bsAb, is in pre­clin­i­cal de­vel­op­ment.

Newspapers in English

Newspapers from India

© PressReader. All rights reserved.